Clinical Trials Logo

Filter by:
NCT ID: NCT05911464 Recruiting - Clinical trials for Advanced Solid Tumor

A Phase I Study of HS-10386 in Participants With Advanced Solid Tumors

Start date: March 2, 2023
Phase: Phase 1
Study type: Interventional

The purpose of this study is to evaluate the safety and tolerability, pharmacokinetics, and preliminary anti-tumor activity of HS-10386 in participants with advanced solid tumors who have failed prior treatments.

NCT ID: NCT05911217 Recruiting - Pancreatic Cancer Clinical Trials

A Study to Evaluate the Efficacy and Safety of CT041 After Adjuvant Chemotherapy for Pancreatic Cancer

Start date: July 11, 2023
Phase: Phase 1
Study type: Interventional

An open-label, single-arm, multicenter, Phase Ib clinical trial to evaluate the efficacy and safety of CT041 Autologous CAR T Cell Injection after adjuvant chemotherapy in subjects with pancreatic cancer.

NCT ID: NCT05911152 Recruiting - Colorectal Cancer Clinical Trials

Safety and Feasibility of Laparoscopic Intracorporeal Anastomosis for Colorectal Surgery- A Multiple Center Real World Study

SELECTED
Start date: January 1, 2016
Phase:
Study type: Observational

The goal of this observational study is to explore the safety and feasibility of laparoscopic intracorporeal anastomosis in colorectal cancer surgery. The main questions it aims to answer are: 1. If intracorporeal anastomosis is safe in terms of short-term outcome? 2. If intracorporeal anastomosis can achieve the same oncological outcome as conventional extracorporeal anastomosis?

NCT ID: NCT05910398 Recruiting - Clinical trials for Breast Cancer Invasive

Continuous or Intermittent Extension of Adjuvant Pyrotinib for Invasive HER2-positive Breast Cancer

CORINNE-PI
Start date: June 1, 2023
Phase: Phase 3
Study type: Interventional

This is a prospective, randomised, controlled, multicentre study to compare the efficacy and safety between continuous or intermittent extension of adjuvant pyrotinib in invasive human epidermal growth factor receptor 2 (HER2)-positive breast cancer.

NCT ID: NCT05910242 Recruiting - Clinical trials for Essential Hypertension

Efficacy and Safety of Remote Ischemic Conditioning in the Treatment of Essential Hypertension (RICBP-EH)

Start date: June 20, 2023
Phase: N/A
Study type: Interventional

The purpose of this study is to determine the efficacy and safety of remote ischemic conditioning in the treatment of essential hypertension.

NCT ID: NCT05910177 Recruiting - Carcinoma Clinical Trials

Neoadjuvant Treatment of Neuroendocrine Cervix Carcinomar With Camrelizumab Combined With Etoposide and Cisplatin

Start date: December 28, 2023
Phase: Phase 2
Study type: Interventional

This study is a single arm, exploratory clinical study aimed at evaluating the efficacy and safety of karelizumab combined with etoposide and cisplatin in the neoadjuvant treatment of neuroendocrine cervix carcinoma.

NCT ID: NCT05909982 Recruiting - Clinical trials for Acute Ischemic Stroke

Ischemic Post-conditioning in Acute Ischemic Stroke Thrombectomy (PROTECT-1b)

PROTECT
Start date: April 1, 2023
Phase: Phase 1/Phase 2
Study type: Interventional

Ischemic post-conditioning is a neuroprotective strategy attenuating reperfusion injury in animal stroke models. The investigators have conducted a 3 + 3 dose-escalation trial to demonstrate the safety and tolerability of ischemic post-conditioning incrementally for a longer duration of up to 5 min × 4 cycles in stroke patients undergoing mechanical thrombectomy. This study aims to assess the infarct volume after ischemic post-conditioning in patients with acute ischemic stroke who are treated with mechanical thrombectomy.

NCT ID: NCT05909904 Recruiting - Clinical trials for Head and Neck Cancer

Tislelizumab in Combination With Investigational Agents in Participants With Head and Neck Squamous Cell Carcinoma

Start date: July 21, 2023
Phase: Phase 2
Study type: Interventional

This study is designed to evaluate the efficacy and safety of tislelizumab and tislelizumab in combination with investigational agent(s) in first-line recurrent or metastatic (R/M) head and neck squamous cell carcinoma (HNSCC).

NCT ID: NCT05909436 Recruiting - Solid Tumor Clinical Trials

Immuno-Oncology Drugs GLS-012 Alone & in Combination GLS-010 Treating With Advanced Patients Solid Tumors

Start date: October 31, 2022
Phase: Phase 1/Phase 2
Study type: Interventional

This is a phase I/II study to investigate the safety, tolerability, and preliminary efficacy of GLS-012 monotherapy and in combination with GLS-010 in subjects with advanced solid rumor after progression on standard treatment.

NCT ID: NCT05909332 Recruiting - Breast Cancer Clinical Trials

Study of Antivascular Therapy Combined With Chemotherapy Versus Chemotherapy in Adjuvant Therapy of TNBC-BLIS Patients (BCTOP-T-A03)

Start date: June 20, 2023
Phase: Phase 3
Study type: Interventional

This is a randomized, open-label phase III clinical trial comparing antivascular therapy combined with standard chemotherapy and standard chemotherapy in adjuvant therapy for patients with triple-negative breast cancer, basal-like/Immune suppressed subtype.